scorecard
  1. Home
  2. stock market
  3. news
  4. Alexion Pharmaceuticals soars 35% after AstraZeneca agrees to $39 billion takeover

Alexion Pharmaceuticals soars 35% after AstraZeneca agrees to $39 billion takeover

Shalini Nagarajan   

Alexion Pharmaceuticals soars 35% after AstraZeneca agrees to $39 billion takeover
  • Alexion Pharmaceuticals soared 35% in pre-market trading after the announcement of its $39 billion acquisition by AstraZeneca.
  • The deal has clear gains for both sides, but AstraZeneca's shares slid 6% after news of the UK firm's biggest purchase ever.
  • "If you don't have cash, don't buy a large company unless it is a once-in-a-lifetime opportunity and has strong strategic merits," a portfolio manager said.

Alexion Pharmaceuticals soared 35% in pre-market trading on Monday after AstraZeneca announced a $39 billion acquisition of the Boston-based drugmaker.

The deal was approved by both boards unanimously and is expected to close in the third quarter of 2021. Alexion shareholders will own about 15% of the combined company. Two members from Alexion's board move to AstraZeneca's board.

Alexion's shares were trading at $163 per share in pre-market trading, up from $120.98 at Friday's close.

The acquisition would combine rare-disease specialist Alexion's strengths with the European drugmaker. AstraZeneca has been in the spotlight recently for its development of a coronavirus vaccine candidate with Oxford University. But the vaccine will be unable to contribute to long-term sales, prompting the need for a broader strategy.

Read More: JPMorgan unveils its 50 'most compelling' stock picks to buy for 2021 - and details why each one will be a top performer

AstraZeneca, which slumped 6% on Monday, expects the acquisition to increase earnings per share by at least 10% over the next three years. Some investors have questioned its planned strategy behind the sizeable acquisition.

"If you don't have cash, don't buy a large company unless it is a once-in-a-lifetime opportunity and has strong strategic merits," Markus Manns at Union Investment told Bloomberg. "You can hardly call this deal a once-in-a-lifetime opportunity, and the strategic merits are weak."

Read More: Buy these 28 discounted stocks from an LGBT-inclusive index that's crushed its global benchmark since 2010, says Credit Suisse

READ MORE ARTICLES ON



Popular Right Now



Advertisement